hepatocellular carcinoma

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma

By MedXY 09/04/2025

SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatments.

Clinical Updates Wellness & Lifestyle

Targeting Oxytocin Receptor: A Novel Strategy Against Hepatocellular Carcinoma Using Atosiban

By MedXY 08/31/2025

Recent research identifies the oxytocin receptor (OXTR) as a critical driver of liver cancer via Hippo/YAP signaling. The FDA-approved tocolytic drug Atosiban shows promise in blocking this pathway, offering new therapeutic avenues in hepatocellular carcinoma management.

Clinical Updates Wellness & Lifestyle

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.

Clinical Updates Wellness & Lifestyle

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.

Clinical Updates Wellness & Lifestyle

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

By MedXY 08/02/2025

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.